Smell improvement by anti-IgE and anti-IL 5 biologics in patients with CRSwNP and severe asthma. A real life study | Zendy

B Barroso | Zendy; Marcela ValverdeMonge | Zendy; I Alobid | Zendy; José M. Rivera | Zendy; Manuel J. Rial | Zendy; Santiago Quirce | Zendy; Ebymar Arismendi | Zendy; P Barranco | Zendy; D Betancor | Zendy; Irina Bobolea | Zendy; Blanca Cárdaba | Zendy; María Jesús Cruz | Zendy; E Curto | Zendy; Javier DomínguezOrtega | Zendy; Francisco Javier GonzálezBarcala | Zendy; Carlos MartínezRivera | Zendy; I Mahíllo-Fernández | Zendy; Xavier Muñoz | Zendy; C Picado | Zendy; V Plaza | Zendy; José M. RodrigoMuñoz | Zendy; L Soto-Retes | Zendy; A Valero | Zendy; V Del Pozo | Zendy; J Mullol | Zendy; J. Sastre | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Smell improvement by anti-IgE and anti-IL 5 biologics in patients with CRSwNP and severe asthma. A real life study

Author(s) -

B Barroso,

Marcela ValverdeMonge,

I Alobid,

José M. Rivera,

Manuel J. Rial,

Santiago Quirce,

Ebymar Arismendi,

P Barranco,

D Betancor,

Irina Bobolea,

Blanca Cárdaba,

María Jesús Cruz,

E Curto,

Javier DomínguezOrtega,

Francisco Javier GonzálezBarcala,

Carlos MartínezRivera,

I Mahíllo-Fernández,

Xavier Muñoz,

C Picado,

V Plaza,

José M. RodrigoMuñoz,

L Soto-Retes,

A Valero,

V Del Pozo,

J Mullol,

J. Sastre

Publication year - 2022

Publication title -

journal of investigational allergology and clinical immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.657

H-Index - 61

eISSN - 1698-0808

pISSN - 1018-9068

DOI - 10.18176/jiaci.0812

Subject(s) - medicine , mepolizumab , hyposmia , omalizumab , olfaction , asthma , benralizumab , nasal polyps , anosmia , immunology , immunoglobulin e , disease , eosinophil , antibody , covid-19 , infectious disease (medical specialty) , neuroscience , biology

Chronic rhinosinusitis with nasal polyps (CRSwNP), which is characterized by partial loss of smell (hyposmia) or total loss of smell (anosmia), is commonly associated with asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). CRSwNP worsens disease severity and quality of life. The objective of this real-world study was to determine whether biological treatments prescribed for severe asthma can improve olfaction in patients with CRSwNP. A further objective was to compare the improvement in in olfaction in N-ERD and non-N-ERD subgroups.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research